First-line treatment for canine coccidioidomycosis is fluconazole or itraconazole administered for a minimum of 6 to 12 months for pulmonary disease, with disseminated infections typically requiring 1 year or more — and often lifelong therapy. Journal of the…+2
Fluconazole is the preferred azole for CNS involvement due to its blood-brain barrier penetration. Journal of the… For CNS coccidioidomycosis, the regionally recommended dose is fluconazole 10 mg/kg PO q12h (20 mg/kg/day total), with a maximum of 400 mg/day. Journal of Vete… The standard published dose is fluconazole 5 mg/kg PO q12h (10 mg/kg/day total), though no controlled comparison of these two doses has been performed. Journal of Vete… For non-CNS disease, fluconazole 4 mg/kg PO q12h has been used in clinical practice. Journal of the… Itraconazole 4 mg/kg PO q24h and itraconazole 4.8 mg/kg PO q24h have both been reported for non-CNS disseminated disease. Journal of the…+1 Ketoconazole is also cited as an alternative to itraconazole for osseous disease. Journal of the…
Compounded fluconazole formulations carry a meaningful risk of treatment failure and should be avoided in favor of generic formulations. Switching dogs from compounded to generic fluconazole at essentially the same prescribed dose resulted in neurologic improvement in 7 dogs with CNS coccidioidomycosis, consistent with evidence that compounded fluconazole provides unreliable serum concentrations. Journal of Vete…
For refractory cases — defined as failure to respond to at least two first-line treatments — posaconazole at 2.5 to 10 mg/kg/day is the recommended escalation. Six of 8 dogs with refractory coccidioidomycosis achieved recovery or clinical remission on posaconazole, with trough serum concentrations of 1.52 to >6 μg/mL. Journal of Vete… Posaconazole was well tolerated in 7 of 8 dogs; 1 dog required dose reduction and ultimately discontinued treatment due to hepatotoxicosis. Journal of Vete… Amphotericin B (IV, potentially nephrotoxic) is an additional option for refractory disease. Journal of Vete…
Treatment monitoring should combine serial serology, clinical signs, and clinicopathologic assessment — serologic titers alone are unreliable as the sole monitoring tool due to individual variability in titer responses. Journal of the… Treatment continuation until the IgG titer is ≤1:2 has been suggested. Journal of the… Serum C-reactive protein and haptoglobin both decrease significantly within the first 3 months of treatment in dogs with pulmonary coccidioidomycosis, with median improvements of 92% and 39% respectively, and relative change in haptoglobin predicts remission. Journal of the… Liver enzyme monitoring is warranted throughout treatment given the risk of hepatotoxicosis with azole therapy. Journal of the…+1 Radiographic recheck every 6 to 8 weeks is recommended to monitor bony and pulmonary changes. Journal of the…
Glucocorticoids and anticonvulsants are recommended adjuncts for CNS disseminated disease. Medical Mycology Dogs with MRI evidence of ventriculitis represent a higher-risk subset — both dogs with ventriculitis in one CNS cohort had an initially favorable response followed by rapid neurologic decline, with one developing obstructive hydrocephalus; ventriculoperitoneal shunting may be beneficial in this subset. Journal of Vete…
Prognosis is disease-distribution dependent. Dogs with pulmonary involvement alone carry a good prognosis. Journal of the…+1 Dogs with CNS or multiple bone involvement carry a guarded to poor prognosis. Journal of the… However, with appropriate medical treatment, 82% of dogs diagnosed with intracranial coccidioidomycosis were alive and clinically well at follow-up ≥1 year after imaging diagnosis. Journal of Vete… Approximately 25% of dogs with coccidioidomycosis experience disease recurrence after cessation of treatment, necessitating long-term monitoring. Journal of the…+1 Conversion to seronegative status is uncommon, and return to seropositivity after drug discontinuation — as occurred within 2 months in one reported case — frequently requires recommencement of therapy. Journal of the… Delayed treatment, poor initial treatment response, and azole-induced hepatotoxicosis are all associated with worse outcomes. Journal of the…
| Drug | Dose / Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| Fluconazole (CNS) | 10 mg/kg PO q12h (max 400 mg/day) | 82% alive and well at ≥1 yr (CNS cohort) Journal of Vete… | Avoid compounded formulations Journal of Vete… |
| Fluconazole (standard) | 5 mg/kg PO q12h | Median treatment duration 298.5 days Journal of the… | No controlled comparison to 10 mg/kg dose Journal of Vete… |
| Itraconazole | 4–4.8 mg/kg PO q24h Journal of the…+1 | Clinical use; itraconazole 72% response at 12 mo in humans Journal of the… | Compounded itraconazole lacks stability Journal of Vete… |
| Posaconazole (refractory) | 2.5–10 mg/kg/day Journal of Vete… | 6/8 dogs achieved remission; median treatment 18 mo Journal of the…+1 | Monitor liver enzymes and trough levels; target >1 μg/mL Journal of Vete… |
Would you like guidance on how to interpret serial coccidioidomycosis IgG titers to decide when it is safe to discontinue antifungal therapy?
